Literature DB >> 15761378

Advanced glycation end-products prepared in solution under high pressure contain epitopes distinct from those formed in the dry reaction at high temperature.

Magdalena Staniszewska1, Jerzy Jarosz, Marek Jon, Andrzej Gamian.   

Abstract

INTRODUCTION: Advanced glycation end-products play an important role in diseases related to diabetes and aging processes. Model compounds are synthesized in order to prepare the diagnostic and experimental tools for studying the mechanisms of pathogenesis. The objective of the present study was to accelerate glycation and upgrade its efficiency under high-pressure conditions. MATERIAL/
METHODS: Aqueous solutions of proteins were kept with carbohydrates under a pressure of up to 850 MPa for several hours. Then the high-pressure glycation (HPG) products were fractionated on a Sephadex G-200 column and characterized with SDS-PAGE and MALDI-TOF mass spectrometry.
RESULTS: The low-molecular-mass fraction of glycated proteins was separated from the two fractions containing high-and intermediate-molecular-mass cross-linked products of glycation. The products were then compared with those obtained with the high-temperature glycation (HTG) procedure carried out in dry conditions with a lyophilized mixture of substrates. The fractionated products were used to prepare rabbit sera.
CONCLUSIONS: The immunoblotting experiments showed that the epitopes on the cross-linked glycation products formed in solution under high pressure differed from those originating in dry conditions at high temperature. Sera against the HPG products were specific to homologous material and did not interact with the fractions obtained by HTG. The antibodies against HTG products recognized HTG but not HPG products.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761378

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  2 in total

1.  Advanced glycation end products as a source of artifacts in immunoenzymatic methods.

Authors:  Aleksandra Kuzan; A Chwiłkowska; K Maksymowicz; A Bronowicka-Szydełko; K Stach; C Pezowicz; A Gamian
Journal:  Glycoconj J       Date:  2018-01-05       Impact factor: 2.916

2.  The Genotoxic and Pro-Apoptotic Activities of Advanced Glycation End-Products (MAGE) Measured with Micronuclei Assay Are Inhibited by Their Low Molecular Mass Counterparts.

Authors:  Monika Czech; Maria Konopacka; Jacek Rogoliński; Zbigniew Maniakowski; Magdalena Staniszewska; Łukasz Łaczmański; Danuta Witkowska; Andrzej Gamian
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.